The AVATAR Foundry is designed to allow AmplifyBio to help clients maximize the potency and tumor-killing activity of their ...

The acquisition of the Vacaville facility significantly extends Lonza’s capacity for mammalian manufacturing in the U.S.

Epigenetic, bioelectromic, synaptic, and senolytic interventions could rejuvenate cells and counter the effects of aging.

By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...

Research by a Stanford University team of scientists has shed new light on how and why neural stem cells (NSCs), the cells ...

KBI Biopharma says they’re selecting the best technologies to fill gaps in their processes with grassroots help from their ...

Industry, academic institutions, suppliers, and regulatory agencies working together can yield state-of-the-art downstream ...

Quell’s proprietary platform has been developed to generate engineered CAR-Treg cell therapies that can be directed to ...

Aptadir engineers RNA therapies that inhibit DNMT-1 to prevent methylation in genes associated with myelodysplastic syndrome and other disorders.

Whereas Biopharma 4.0 prioritizes productivity, Biopharma 5.0 emphasizes environmental and social sustainability.

Poseida Therapeutics' lead allogeneic chimeric antigen receptor T-cell candidate it is co-developing with Roche will advance to Phase Ib.

Researchers recommend verifying success of column-based purification to confirm the presence and availability of the tag on target protein.